188 results on '"Weinkove, Robert"'
Search Results
2. Sepsis mortality among patients with haematological malignancy admitted to intensive care 2000–2022: a binational cohort study
3. A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
4. Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies
5. Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy
6. Temperature management in haematology patients with febrile neutropenia : a practice survey
7. Tuning CAR T-cell therapies for efficacy and reduced toxicity
8. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
9. Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis
10. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis
11. Human induced-T-to-natural killer cells have potent anti-tumour activities
12. IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells
13. Neutropenic Sepsis in the Intensive Care Unit: Differences in Clinical Profile and Outcomes According to the Cause of Neutropenia.
14. Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
15. Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey.
16. Immunology across two islands: understanding the research landscape of Aotearoa (New Zealand).
17. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
18. CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
19. Australia and New Zealand consensus position statement: use of COVID‐19 therapeutics in patients with haematological malignancies.
20. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
21. Correction to: A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
22. A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
23. An In Vitro Model to Assess CRS Potential of CAR T Cells Using a Tumor Cell Line and Autologous Monocytes.
24. Engaging Natural Killer T Cells as ‘Universal Helpers’ for Vaccination
25. An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment
26. Central venous access device practice across haematology and oncology centres in Australia and New Zealand: a cross‐sectional survey.
27. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
28. Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
29. Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID‐19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.
30. Association between early peak temperature and mortality in neutropenic sepsis
31. S145: VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY.
32. Glycolipid‐peptide conjugate vaccines elicit CD8+ T‐cell responses and prevent breast cancer metastasis.
33. Fever and pancytopenia in a patient with Crohnʼs disease
34. Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
35. Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
36. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
37. Invariant natural killer T cells and asthma: Immunologic reality or methodologic artifact?
38. Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021.
39. Mucosal-Associated Invariant T (MAIT) Cell Dysfunction and PD-1 Expression in Prostate Cancer: Implications for Immunotherapy.
40. Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
41. Zidovudine-induced pure red cell aplasia presenting after 4 years of therapy
42. COVID‐19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.
43. Venetoclax and obinutuzumab in chronic lymphocytic leukemia
44. Chimeric antigen receptor T‐cell therapies: Optimising the dose.
45. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance.
46. Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial.
47. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
48. B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib
49. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
50. Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.